Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation.
D019386:Alendronate / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects; D001862:Bone Resorption / Q000517:prevention & control*; D002117:Calcitriol / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002118:Calcium / Q000097:blood / Q000652:urine; D003094:Collagen / Q000097:blood; D024042:Collagen Type I; D005260:Female; D050723:Fractures, Bone / Q000517:prevention & control; D016027:Heart Transplantation; D006801:Humans; D007165:Immunosuppression Therapy; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood; D010455:Peptides / Q000097:blood; D011183:Postoperative Complications / Q000517:prevention & control*
D024042:Collagen Type I; D010281:Parathyroid Hormone; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide; D003094:Collagen; D002117:Calcitriol; D002118:Calcium; D019386:Alendronate